Hepatitis C virus and renal transplantation

Area of Science:

• Hepatology
• Nephrology
• Transplantation Immunology

Background:

• Hepatitis C virus (HCV) infection is a significant concern following renal transplantation.
• Emerging evidence highlights HCV as the most critical liver disease in this patient population.
• Fibrosing cholestatic hepatitis is a rare but severe complication that can lead to early liver failure.

Purpose of the Study:

• To review the impact of hepatitis C virus infection on outcomes after renal transplantation.
• To assess the efficacy of ribavirin in managing HCV post-transplant.
• To evaluate graft and patient survival rates in HCV-positive versus HCV-negative renal transplant recipients.

Main Methods:

• Review of recent studies and clinical evidence regarding HCV in renal transplant recipients.
• Analysis of patient and graft survival data.
• Assessment of complications such as fibrosing cholestatic hepatitis and glomerular lesions.
• Evaluation of treatment outcomes with ribavirin.

Main Results:

• Hepatitis C virus infection is the most significant liver disease after renal transplantation.
• Fibrosing cholestatic hepatitis can cause early liver failure, with long-term complications also noted.
• Ribavirin has demonstrated encouraging results in managing HCV post-transplant.
• Graft and patient survival rates are similar between HCV-positive and HCV-negative patients.
• HCV-positive patients exhibit better survival post-transplant compared to those on dialysis.

Conclusions:

• Hepatitis C virus infection requires careful management in renal transplant recipients.
• Despite potential complications, renal transplantation offers better survival for HCV-positive patients than remaining on dialysis.
• Consideration should be given to using kidneys from HCV-positive donors for compatible HCV RNA-positive recipients, matching the HCV genotype.